Close
Smartlab Europe
Inizio Ignite

Alto Pharma to introduce DermSafe hand sanitizer

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Lilly Zepbound-Taltz Combo Gains Ground with Phase 3b Data

Eli Lilly said that its weight-loss medicine Zepbound, when...

J&J to Invest $1 Billion in Pennsylvania Cell Therapy Plant

Johnson & Johnson announced that it plans to invest...

Precision Cellular Analysis Powering the Next Generation

Biopharmaceutical innovation increasingly depends on understanding biology at the...
- Advertisement -
Smart Lab Europe

Alto Pharmaceuticals is set to introduce Skinvisible Pharmaceuticals’ DermSafe antimicrobial hand sanitizer in Canada on 1 September 2011.Under an agreement signed between both the companies, Skinvisible has given Canadian marketing rights of DermSafe to Alto. Alto expects to market the product under the name DermSafePC.DermSafe is made with 4% chlorhexidine gluconate and it does not contain delivers protection in a lotion formulation that defends the skin from outside irritants.Skinvisible president and CEO Terry Howlett said they believe that the introduction of DermSafePC will help generate a very positive response from end-users as well as potential licensees worldwide.

“The manufacturing of DermSafe in Canada is critical to Skinvisible as it will facilitate the quick introduction of the product in Europe and Singapore, where DermSafe is already approved for importation,” Howlett said.

Smart Lab Europe

Latest stories

Related stories

Lilly Zepbound-Taltz Combo Gains Ground with Phase 3b Data

Eli Lilly said that its weight-loss medicine Zepbound, when...

J&J to Invest $1 Billion in Pennsylvania Cell Therapy Plant

Johnson & Johnson announced that it plans to invest...

Precision Cellular Analysis Powering the Next Generation

Biopharmaceutical innovation increasingly depends on understanding biology at the...

FDA Approves Monthly Rybrevant Faspro for EGFR-Mutated NSCLC

Johnson & Johnson (J&J) has obtained approval from the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »